BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biswas S, Sengupta S, Roy Chowdhury S, Jana S, Mandal G, Mandal PK, Saha N, Malhotra V, Gupta A, Kuprash DV. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res Treat. 2014;143:265-276. [PMID: 24337540 DOI: 10.1007/s10549-013-2811-8] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Meng X, Yu X, Dong Q, Xu X, Li J, Xu Q, Ma J, Zhou C. Distribution of circulating follicular helper T cells and expression of interleukin-21 and chemokine C-X-C ligand 13 in gastric cancer. Oncol Lett. 2018;16:3917-3922. [PMID: 30128008 DOI: 10.3892/ol.2018.9112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
2 Zhang J, Huang S, Quan L, Meng Q, Wang H, Wang J, Chen J. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian Cancer by Bioinformatics Analysis. Biomed Res Int 2021;2021:8883800. [PMID: 33829065 DOI: 10.1155/2021/8883800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662-80. [PMID: 32753728 DOI: 10.1038/s41568-020-0285-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 117] [Article Influence: 122.0] [Reference Citation Analysis]
4 Ohandjo AQ, Liu Z, Dammer EB, Dill CD, Griffen TL, Carey KM, Hinton DE, Meller R, Lillard JW Jr. Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment. Sci Rep 2019;9:14963. [PMID: 31628349 DOI: 10.1038/s41598-019-46491-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
5 Alluri SR, Higashi Y, Kil KE. PET Imaging Radiotracers of Chemokine Receptors. Molecules 2021;26:5174. [PMID: 34500609 DOI: 10.3390/molecules26175174] [Reference Citation Analysis]
6 Liu H, Yang Z, Lu W, Chen Z, Chen L, Han S, Wu X, Cai T, Cai Y. Chemokines and chemokine receptors: A new strategy for breast cancer therapy. Cancer Med 2020;9:3786-99. [PMID: 32253815 DOI: 10.1002/cam4.3014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
7 Jiao F, Sun H, Yang Q, Sun H, Wang Z, Liu M, Chen J. Association of CXCL13 and Immune Cell Infiltration Signature in Clear Cell Renal Cell Carcinoma. Int J Med Sci 2020;17:1610-24. [PMID: 32669964 DOI: 10.7150/ijms.46874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Zhang G, Miao F, Xu J, Wang R. Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13. Bosn J Basic Med Sci 2020;20:209-17. [PMID: 31538911 DOI: 10.17305/bjbms.2019.4344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mandal G, Biswas S, Roy Chowdhury S, Chatterjee A, Purohit S, Khamaru P, Chakraborty S, Mandal PK, Gupta A, de la Mare JA, Edkins AL, Bhattacharyya A. Heterodimer formation by Oct4 and Smad3 differentially regulates epithelial-to-mesenchymal transition-associated factors in breast cancer progression. Biochim Biophys Acta Mol Basis Dis 2018;1864:2053-66. [PMID: 29526821 DOI: 10.1016/j.bbadis.2018.03.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Kim SJ, Ryu KJ, Hong M, Ko YH, Kim WS. The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients. J Hematol Oncol 2015;8:49. [PMID: 25966773 DOI: 10.1186/s13045-015-0142-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
11 Panis C, Pizzatti L, Herrera AC, Corrêa S, Binato R, Abdelhay E. Label-Free Proteomic Analysis of Breast Cancer Molecular Subtypes. J Proteome Res 2014;13:4752-72. [DOI: 10.1021/pr500676x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
12 Zhou J, Xiang Y, Yoshimura T, Chen K, Gong W, Huang J, Zhou Y, Yao X, Bian X, Wang JM. The role of chemoattractant receptors in shaping the tumor microenvironment. Biomed Res Int 2014;2014:751392. [PMID: 25110692 DOI: 10.1155/2014/751392] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
13 Zheng Z, Cai Y, Chen H, Chen Z, Zhu D, Zhong Q, Xie W. CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma. Front Oncol 2018;8:682. [PMID: 30723697 DOI: 10.3389/fonc.2018.00682] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 16.0] [Reference Citation Analysis]
14 Kramer Z, Kenessey I, Gángó A, Lendvai G, Kulka J, Tőkés AM. Cell polarity and cell adhesion associated gene expression differences between invasive micropapillary and no special type breast carcinomas and their prognostic significance. Sci Rep 2021;11:18484. [PMID: 34531452 DOI: 10.1038/s41598-021-97347-8] [Reference Citation Analysis]
15 Li Y, Zhou X, Zhang Q, Chen E, Sun Y, Ye D, Wang O, Zhang X, Lyu J. Lipase member H is a downstream molecular target of hypoxia inducible factor-1α and promotes papillary thyroid carcinoma cell migration in BCPAP and KTC-1 cell lines. Cancer Manag Res 2019;11:931-41. [PMID: 30774423 DOI: 10.2147/CMAR.S183355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Gao D, Fish EN. Chemokines in breast cancer: Regulating metabolism. Cytokine 2018;109:57-64. [PMID: 29903574 DOI: 10.1016/j.cyto.2018.02.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
17 Zhao Q, Guo J, Wang G, Bi Y, Cheng X, Liao Y, Jin S, Li L, Guo Y, Pan L, Zhang X, Tan Y, Zhou G, Yu X. CXCL13 promotes intestinal tumorigenesis through the activation of epithelial AKT signaling. Cancer Lett 2021;511:1-14. [PMID: 33894331 DOI: 10.1016/j.canlet.2021.04.012] [Reference Citation Analysis]
18 DeVito NC, Plebanek MP, Theivanthiran B, Hanks BA. Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. Front Immunol 2019;10:2876. [PMID: 31921140 DOI: 10.3389/fimmu.2019.02876] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
19 Hou KZ, Fu ZQ, Gong H. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World J Gastroenterol 2015; 21(2): 475-483 [PMID: 25593462 DOI: 10.3748/wjg.v21.i2.475] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
20 Huang H, Lennikov A. CXCR5/NRF2 double knockout mice develop retinal degeneration phenotype at early adult age. Exp Eye Res 2020;196:108061. [PMID: 32387618 DOI: 10.1016/j.exer.2020.108061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Colineau L, Rouers A, Yamamoto T, Xu Y, Urrutia A, Pham HP, Cardinaud S, Samri A, Dorgham K, Coulon PG, Cheynier R, Hosmalin A, Oksenhendler E, Six A, Kelleher AD, Zaunders J, Koup RA, Autran B, Moris A, Graff-Dubois S. HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation. PLoS One 2015;10:e0140978. [PMID: 26501424 DOI: 10.1371/journal.pone.0140978] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
22 Xu L, Liang Z, Li S, Ma J. Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer. Oncol Lett 2018;15:9293-8. [PMID: 29844827 DOI: 10.3892/ol.2018.8510] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Garaud S, Willard-Gallo K. IRF5: a rheostat for tumor-infiltrating lymphocyte trafficking in breast cancer? Immunol Cell Biol 2015;93:425-6. [PMID: 26010613 DOI: 10.1038/icb.2015.39] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
24 Xing J, Li X, Sui J, Cao G, Fu C. C-X-C chemokine receptor type 5 gene polymorphism affects gene expression in CD4+ T cells and is associated with increased risk of colorectal cancer. Tumor Biol 2014;35:7929-34. [DOI: 10.1007/s13277-014-2069-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Zhu L, Zhang G, Wang P, Zhang L, Ji J, Liu X, Zhou Z, Zhao J, Wang X. The effect of C-X-C motif chemokine ligand 13 in cutaneous squamous cell carcinoma treated with aminolevulinic acid-photodynamic therapy. Photodiagnosis and Photodynamic Therapy 2019;26:389-94. [DOI: 10.1016/j.pdpdt.2019.04.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Hussain M, Adah D, Tariq M, Lu Y, Zhang J, Liu J. CXCL13/CXCR5 signaling axis in cancer. Life Sci 2019;227:175-86. [PMID: 31026453 DOI: 10.1016/j.lfs.2019.04.053] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 15.5] [Reference Citation Analysis]
27 Pang MF, Georgoudaki AM, Lambut L, Johansson J, Tabor V, Hagikura K, Jin Y, Jansson M, Alexander JS, Nelson CM. TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis. Oncogene. 2015; May 11. [Epub ahead of print]. [PMID: 25961925 DOI: 10.1038/onc.2015.133] [Cited by in Crossref: 167] [Cited by in F6Publishing: 167] [Article Influence: 27.8] [Reference Citation Analysis]
28 Curtaz CJ, Schmitt C, Herbert SL, Feldheim J, Schlegel N, Gosselet F, Hagemann C, Roewer N, Meybohm P, Wöckel A, Burek M. Serum-derived factors of breast cancer patients with brain metastases alter permeability of a human blood-brain barrier model. Fluids Barriers CNS 2020;17:31. [PMID: 32321535 DOI: 10.1186/s12987-020-00192-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Wang GZ, Cheng X, Zhou B, Wen ZS, Huang YC, Chen HB, Li GF, Huang ZL, Zhou YC, Feng L, Wei MM, Qu LW, Cao Y, Zhou GB. The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution. Elife 2015;4:e09419. [PMID: 26565418 DOI: 10.7554/eLife.09419] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
30 Chen L, Huang Z, Yao G, Lyu X, Li J, Hu X, Cai Y, Li W, Li X, Ye C. The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer. J Transl Med 2015;13:168. [PMID: 25990390 DOI: 10.1186/s12967-015-0521-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
31 Rubio AJ, Porter T, Zhong X. Duality of B Cell-CXCL13 Axis in Tumor Immunology. Front Immunol 2020;11:521110. [PMID: 33193299 DOI: 10.3389/fimmu.2020.521110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Hussain M, Liu J, Wang GZ, Zhou GB. CXCL13 Signaling in the Tumor Microenvironment. Adv Exp Med Biol 2021;1302:71-90. [PMID: 34286442 DOI: 10.1007/978-3-030-62658-7_6] [Reference Citation Analysis]
33 Koelwyn GJ, Newman AAC, Afonso MS, van Solingen C, Corr EM, Brown EJ, Albers KB, Yamaguchi N, Narke D, Schlegel M, Sharma M, Shanley LC, Barrett TJ, Rahman K, Mezzano V, Fisher EA, Park DS, Newman JD, Quail DF, Nelson ER, Caan BJ, Jones LW, Moore KJ. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat Med 2020;26:1452-8. [PMID: 32661390 DOI: 10.1038/s41591-020-0964-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 20.0] [Reference Citation Analysis]
34 Gao D, Cazares LH, Fish EN. CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis. BMC Cancer 2017;17:834. [PMID: 29216863 DOI: 10.1186/s12885-017-3817-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
35 Garg R, Blando JM, Perez CJ, Abba MC, Benavides F, Kazanietz MG. Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. Cell Rep 2017;19:375-88. [PMID: 28402859 DOI: 10.1016/j.celrep.2017.03.042] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 11.8] [Reference Citation Analysis]
36 Pimenta EM, De S, Weiss R, Feng D, Hall K, Kilic S, Bhanot G, Ganesan S, Ran S, Barnes BJ. IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5 + B‐ and T‐cell trafficking to tumor‐conditioned media. Immunol Cell Biol 2015;93:486-99. [DOI: 10.1038/icb.2014.110] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
37 Lei CS, Jiang Q, Yu Q, Qiu L. Cutaneous plaque in adult T cell leukemia/lymphoma: A case report. Medicine (Baltimore) 2020;99:e23491. [PMID: 33327284 DOI: 10.1097/MD.0000000000023491] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Li BH, Garstka MA, Li ZF. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol Immunol 2020;117:201-15. [PMID: 31835202 DOI: 10.1016/j.molimm.2019.11.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
39 Sahu SK, Tiwari N, Pataskar A, Zhuang Y, Borisova M, Diken M, Strand S, Beli P, Tiwari VK. FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development. Nat Commun 2017;8:1523. [PMID: 29142217 DOI: 10.1038/s41467-017-01366-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
40 Wagner JN, Weis S, Kubasta C, Panholzer J, von Oertzen TJ. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients. J Neurol 2018;265:74-81. [PMID: 29134272 DOI: 10.1007/s00415-017-8669-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
41 Weinstein AM, Storkus WJ. Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. Adv Cancer Res 2015;128:197-233. [PMID: 26216634 DOI: 10.1016/bs.acr.2015.04.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
42 Liu Y, Wang C, Cai N, Long S, Yu F. Negatively charged gold nanoparticles as an intrinsic peroxidase mimic and their applications in the oxidation of dopamine. J Mater Sci 2014;49:7143-50. [DOI: 10.1007/s10853-014-8422-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
43 Karlsson MC, Gonzalez SF, Welin J, Fuxe J. Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol 2017;11:781-91. [PMID: 28590032 DOI: 10.1002/1878-0261.12092] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 15.5] [Reference Citation Analysis]
44 Chen Z, Huang Y, Hu Z, Zhao M, Li M, Bi G, Zheng Y, Liang J, Lu T, Jiang W, Xu S, Zhan C, Xi J, Wang Q, Tan L. Landscape and dynamics of single tumor and immune cells in early and advanced-stage lung adenocarcinoma. Clin Transl Med 2021;11:e350. [PMID: 33783985 DOI: 10.1002/ctm2.350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Li B, Su H, Cao J, Zhang L. CXCL13 rather than IL-31 is a potential indicator in patients with hepatocellular carcinoma. Cytokine 2017;89:91-7. [PMID: 27663978 DOI: 10.1016/j.cyto.2016.08.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
46 Zhang M, Wu JS, Xian HC, Chen BJ, Wang HF, Yu XH, Pang X, Dai L, Jiang J, Liang XH, Tang YL. CXCR5 induces perineural invasion of salivary adenoid cystic carcinoma by inhibiting microRNA-187. Aging (Albany NY) 2021;13:15384-99. [PMID: 34114971 DOI: 10.18632/aging.203097] [Reference Citation Analysis]
47 Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H, Lenz HJ. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev 2019;73:10-9. [PMID: 30551036 DOI: 10.1016/j.ctrv.2018.12.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
48 Yang X, Ma Z, Zhang Y, Wu J, Huang J, Zhao W, Mo F, Lin Z, Xu Y, Zhou Z, Chen S. Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma. Int Immunopharmacol 2020;80:106211. [PMID: 31972424 DOI: 10.1016/j.intimp.2020.106211] [Reference Citation Analysis]
49 Gao HF, Cheng CS, Tang J, Li Y, Chen H, Meng ZQ, Chen Z, Chen LY. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Aging (Albany NY) 2020;12:502-17. [PMID: 31913856 DOI: 10.18632/aging.102638] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
50 Liu Y, Wang J, Ni T, Wang L, Wang Y, Sun X. CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells. Oncotarget 2016;7:25328-39. [PMID: 27015366 DOI: 10.18632/oncotarget.8291] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
51 Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem 2018;119:5028-42. [PMID: 29327370 DOI: 10.1002/jcb.26663] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
52 Trager MH, Rizk E, Rose S, Zhu K, Lau B, Fullerton BT, Pradhan J, Moore M, Srivastava AC, Singer G, Gartrell R, Chang R, Geskin LJ, Saenger YM, Goldenberg G. Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non responders. Sci Rep 2021;11:8775. [PMID: 33888854 DOI: 10.1038/s41598-021-88424-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Boyle ST, Ingman WV, Poltavets V, Faulkner JW, Whitfield RJ, McColl SR, Kochetkova M. The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells. Oncogene 2016;35:105-15. [PMID: 25772241 DOI: 10.1038/onc.2015.66] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
54 Liu W, Zhou X, Wang A, Ma J, Bai Y. Increased peripheral helper T cells type 17 subset correlates with the severity of psoriasis vulgaris. Immunol Lett 2021;229:48-54. [PMID: 33232721 DOI: 10.1016/j.imlet.2020.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Mitkin NA, Hook CD, Schwartz AM, Biswas S, Kochetkov DV, Muratova AM, Afanasyeva MA, Kravchenko JE, Bhattacharyya A, Kuprash DV. p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells. Sci Rep 2015;5:9330. [PMID: 25786345 DOI: 10.1038/srep09330] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
56 Zhu Z, Zhang X, Guo H, Fu L, Pan G, Sun Y. CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway. Mol Cell Biochem. 2015;400:287-295. [PMID: 25476740 DOI: 10.1007/s11010-014-2285-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
57 Lu LL, Chen XH, Zhang G, Liu ZC, Wu N, Wang H, Qi YF, Wang HS, Cai SH, Du J. CCL21 Facilitates Chemoresistance and Cancer Stem Cell-Like Properties of Colorectal Cancer Cells through AKT/GSK-3β/Snail Signals. Oxid Med Cell Longev 2016;2016:5874127. [PMID: 27057280 DOI: 10.1155/2016/5874127] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
58 Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JW Jr, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget 2014;5:10170-9. [PMID: 25296976 DOI: 10.18632/oncotarget.2526] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
59 Mitkin NA, Muratova AM, Sharonov GV, Korneev KV, Sviriaeva EN, Mazurov D, Schwartz AM, Kuprash DV. p63 and p73 repress CXCR5 chemokine receptor gene expression in p53-deficient MCF-7 breast cancer cells during genotoxic stress. Biochim Biophys Acta Gene Regul Mech 2017;1860:1169-78. [PMID: 29107083 DOI: 10.1016/j.bbagrm.2017.10.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
60 Bayer CM, Beckmann MW, Fasching PA. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment. Current Opinion in Obstetrics & Gynecology 2017;29:4-11. [DOI: 10.1097/gco.0000000000000333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
61 Naumnik W, Panek B, Ossolińska M, Naumnik B. B Cell-Attracting Chemokine-1 and Progranulin in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer: New Prognostic Factors. Adv Exp Med Biol 2019;1150:11-6. [PMID: 30357709 DOI: 10.1007/5584_2018_285] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Yue Z, Ningning D, Lin Y, Jianming Y, Hongtu Z, Ligong Y, Feng L, Shuaibo W, Yousheng M. Correlation between CXCR4, CXCR5 and CCR7 expression and survival outcomes in patients with clinical T1N0M0 non-small cell lung cancer. Thorac Cancer 2020;11:2955-65. [PMID: 32896997 DOI: 10.1111/1759-7714.13645] [Reference Citation Analysis]
63 Xu T, Ruan H, Song Z, Cao Q, Wang K, Bao L, Liu D, Tong J, Yang H, Chen K, Zhang X. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis. Biomed Pharmacother 2019;118:109264. [PMID: 31390578 DOI: 10.1016/j.biopha.2019.109264] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
64 Fan L, Zhu Q, Liu L, Zhu C, Huang H, Lu S, Liu P. CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion. Oncotarget 2017;8:53244-61. [PMID: 28881808 DOI: 10.18632/oncotarget.18387] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
65 Wang D, Hu K, Gao N, Zhang H, Jiang Y, Liu C, Wang S, Zhao Z. High throughput screening of cytokines, chemokines and matrix metalloproteinases in wound fluid induced by mammary surgery. Oncotarget 2015;6:29296-310. [PMID: 26313265 DOI: 10.18632/oncotarget.4828] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
66 Chao CC, Lee WF, Wang SW, Chen PC, Yamamoto A, Chang TM, Weng SL, Liu JF. CXC chemokine ligand-13 promotes metastasis via CXCR5-dependent signaling pathway in non-small cell lung cancer. J Cell Mol Med 2021;25:9128-40. [PMID: 34427969 DOI: 10.1111/jcmm.16743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 King J, Mir H, Singh S. Association of Cytokines and Chemokines in Pathogenesis of Breast Cancer. Approaches to Understanding Breast Cancer. Elsevier; 2017. pp. 113-36. [DOI: 10.1016/bs.pmbts.2017.07.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
68 Gao D, Rahbar R, Fish EN. CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open Biol 2016;6:160122. [PMID: 27335323 DOI: 10.1098/rsob.160122] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
69 Mandal PK, Biswas S, Mandal G, Purohit S, Gupta A, Majumdar (Giri) A, Roy Chowdhury S, Bhattacharyya A. CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-β-induced breast cancer progression. Immunobiology 2018;223:151-61. [DOI: 10.1016/j.imbio.2017.10.031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
70 Biswas S, Roy Chowdhury S, Mandal G, Purohit S, Gupta A, Bhattacharyya A. RelA driven co-expression of CXCL13 and CXCR5 is governed by a multifaceted transcriptional program regulating breast cancer progression. Biochim Biophys Acta Mol Basis Dis 2019;1865:502-11. [PMID: 30553016 DOI: 10.1016/j.bbadis.2018.12.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]